Plain-English translation of NCT07286214 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether a medication called can help people with polymyalgia rheumatica — a condition that causes muscle pain and stiffness, usually in people over 50 — manage their symptoms more effectively. You would receive either the medication or placebo (a dummy injection) every two weeks for 52 weeks, along with a gradually decreasing dose of prednisone, a steroid that helps control inflammation. Researchers want to see if this treatment helps reduce pain and allows patients to use less steroid medicine overall.
Many people with polymyalgia rheumatica need high doses of steroids for long periods, which can cause serious side effects. This medication is being studied to see if it could help control the condition with lower steroid doses, making treatment safer and more tolerable.
You likely qualify if…
You likely don't qualify if…
You would visit the clinic about 14 times over 58 weeks. At your first visit, you would be randomly assigned to receive either injections, a higher dose of injections, or placebo injections — all given every two weeks — along with prednisone that gradually decreases over 52 weeks. You would have clinic visits roughly every 2–4 weeks where staff would check your symptoms, do blood tests, and give you your injection. The study ends with a final follow-up visit 6 weeks after your last injection.
AI-generated summary from trial data · Sep 2, 2026 · Not medical advice
United States